Investors File Securities Suit Against Regencell as Firms Seek Lead Plaintiff

The litigation follows Regencell's disclosure of a DOJ subpoena into trading that the company said could trigger significant legal costs and losses for shareholders.

Overview

Regencell disclosed in an SEC filing that the U.S. Department of Justice had sent correspondence and a subpoena about trading in the company's ordinary shares, a disclosure that plaintiffs cite as the central trigger for the case.
The complaint alleges that between October 28, 2024 and October 31, 2025 the company failed to tell investors it was vulnerable to market manipulation and that its public statements were therefore misleading.
After the DOJ disclosure the stock moved sharply, with filings noting an 18.56% decline to $13.56 per share reported in early November 2025 that plaintiffs say reflects investor harm.
Multiple plaintiff firms have filed or are pursuing the federal securities class action and are actively soliciting investors to move for appointment as lead plaintiff by the June 23, 2026 court deadline.
Regencell has warned the DOJ inquiry remains unresolved, that it expects ongoing legal costs and potential fines or settlements that could exceed insurance coverage, and that resolution could take months or years with uncertain outcomes for shareholders.